24/7 Patient Assistance: 760-405-8205

David Minor, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. David Minor completed his medical school at the University of California, San Francisco. He did his residency in internal medicine at the California Pacific Medical Center-California Campus. He also completed a fellowship in medical oncology at the Yale-New Haven Hospital. He is a board-certified oncologist licensed to practice in the State of California. Dr. Minor has been in clinical practice for 20 years and is currently affiliated with the Saint Francis Memorial Hospital. He has also contributed to over 25 research publications.



  • Education & Training

    dept_icon

    University of California San Francisco

    Medical School

    dept_icon

    California Pacific Medical Center - California Campus

    Residency

    dept_icon

    Yale-New Haven Hospital

    Fellowship

  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Saint Francis Memorial Hospital

    Languages: English/Spanish

    (415) 353-6000

    900 Hyde St

    San Francisco, California 94109

    Read More
  • Publications & Memberships

    Dr. David Minor has contributed to 3 publications.

    Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.

    Ascierto, P. A.,Minor, D.,Ribas, A.,Lebbe, C.,O'Hagan, A.,Arya, N.,Guckert, M.,Schadendorf, D.,Kefford, R. F.,Grob, J. J.,Hamid, O.,Amaravadi, R.,Simeone, E.,Wilhelm, ...; J. Clin. Oncol.. 2013 Sep 10.

    See more >>

    Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.

    Minor, D. R.,Bunker, S. R.,Doyle, J.; J. Clin. Oncol.. 2013 Jul 10.

    See more >>

    Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.

    Fadaki, N., Cardona-Huerta, S., Martineau, L., Thummala, S., Cheng, S. T., Bunker, S. R., Garcia-Kennedy, R., Wang, W., Minor, D., Kashani-Sabet, M., Leong, S. P.; BMJ Case Rep. 2012.

    See more >>